Pharmafile Logo

What we do and who we do it for | Pegasus

We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital and social. One that creates all of its content in-house. One that’s transparent and measurable.

Why? Because health conversations are happening everywhere, all of the time. Every day we all make decisions that impact on the quality of our own, and often other people’s, health. From the food we eat, the products we put on our skin, the medicines we take or the routines we create to prevent or manage illness. We might be a healthcare professional, a policy maker, a businessman, a patient, a parent or a combination of all these. We could be in a doctor’s surgery, at home, in the gym, or on the go. Whoever we are, wherever we are, and whatever we are doing, the ability to make healthy decisions, consciously or not, will benefit us as individuals and beyond.

This is a new approach to health communications.

This is Pegasus.

Find out more at info@thisispegasus.co.uk or by calling +44 (0) 1273 712 000.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....

Delivering multi-stakeholder patient journey insights in oncology with creative outputs and data visualisation

Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an...